Centre Testing International Group (300012) Fair Value & Analysis
Industrials · CN · Market cap 23.6B CNY
Analysis
Centre Testing International Group (300012) currently trades at ¥14.60, while our model-based Fair Value estimate is ¥12.68 — implying the stock looks roughly 13.2% overvalued today. We read business quality at 92/100 (high quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Centre Testing International Group Co. Ltd. provides testing, inspection, certification, calibration, audit, training, and technical services in China and internationally. It operates in five segments: Trade Protection; Consumer Product Testing; Industrial Testing; Life Sciences; and Pharmaceuticals and Medical Services. The company offers environmental protection and regulatory; in-vehicle electronics; vehicle and parts; connectors and fasteners; rail transit; hazardous substances in vessel; aviation materials; special equipment; toys; home supplies; furniture and furniture materials; food contact material; table and kitchenware; medical device; electromagnetic compatibility; safety compliance; reliability; green/ environmental protection; construction works; combustion performance; foundation and on-site physical inspection; construction site monitory/measurement; building material testing; CTI sets; food and product type inspection; pet food and feed; agricultural materials; heal…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.